Pfizer reports tasocitinib data for RA

Pfizer Inc. (NYSE:PFE) said twice-daily oral tasocitinib met two of three co-primary endpoints in the Phase III ORAL Solo (1045) trial to treat moderate to severe active rheumatoid arthritis. The Janus kinase-3 (JAK-3) inhibitor significantly improved ACR20 response rate and mean HAQ-DI scores from baseline to three months vs. placebo; however, it missed the third co-primary endpoint of a significantly greater proportion of patients achieving a DAS28 score of less than 2.6 vs. placebo. The double-blind trial enrolled 611 patients with RA who had an inadequate response to one or more DMARDs. ...